Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Combined Neurosurgical and Gastrointestinal Surgical Approach Using Omental Flap for Adult Currarino Syndrome: A Case Report.

NMC case report journal·2026
Same author

Bilateral intradiploic dermoid cysts with unilateral rupture causing hearing loss: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

Efficacy Endpoint Standardization in Adult Primary CNS Tumor Trials: Integrating Regulatory Science and Clinical Perspectives in the RANO 2.0 Era.

Cancers·2026
Same author

Possible involvement of genome-wide near-haploidy and <i>MEN1</i> mutation in the molecular pathogenesis of pituitary carcinoma: Analysis by whole exome sequencing.

Neuro-oncology advances·2026
Same author

A response to the letter regarding "<i>Minimally invasive surgery for remnant gastric cancer: a single-center retrospective study of treatment outcomes in Japan</i>".

Journal of minimally invasive surgery·2026
Same author

Association between time to surgery and survival in patients with initially diagnosed WHO 2021 grade 4 gliomas.

Neuro-oncology advances·2026

相关实验视频

Updated: Jun 13, 2025

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K

PIK3R2免疫染状态预测了新诊断的质母细胞瘤患者的预后,这些患者接受了自身瘤疫苗的治疗.

Kazuki Akutagawa1, Shunichiro Miki1, Erika Yamada1

  • 1Department of Neurosurgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki Prefecture, 305-8575, Japan.

Journal of neuro-oncology
|June 12, 2025
PubMed
概括

负的PIK3R2和p53表达预测了接受自主形式素固定瘤疫苗 (AFTV) 治疗的质母细胞瘤患者的更好的生存率. 这些生物标志物可能有助于预测AFTV治疗疗效和患者结果.

关键词:
质母细胞瘤 (glioblastoma) 是一个免疫治疗是一种免疫疗法.通过PI3K路径.这就是PIK3R2的原因.预测 预后 预测 预测这是瘤疫苗.

更多相关视频

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.9K
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

9.6K

相关实验视频

Last Updated: Jun 13, 2025

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.9K
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

9.6K

科学领域:

  • 神经瘤学神经瘤学
  • 免疫治疗是一种免疫疗法.
  • 分子生物学分子生物学

背景情况:

  • 质母细胞瘤 (GBM) 是一种具有不良预后和有限治疗选择的侵袭性脑瘤.
  • 之前的研究表明,完全切除和p53阴性与接受放射治疗,temozolomide和自主甲固定瘤疫苗 (AFTV) 治疗的GBM患者的更好的结果相关.
  • 作为PI3K-Akt通路组成部分的PIK3R2可能会影响免疫反应和免疫疗法的有效性,这促使人们对其在AFTV治疗中的预后作用进行调查.

研究的目的:

  • 为了研究PIK3R2表达是否影响新诊断的质母细胞瘤 (GBM) 和4级星系细胞瘤 (Astro) 患者的患者结局,用AFTV治疗.
  • 评估PIK3R2作为AFTV治疗疗效的潜在预测生物标志物.

主要方法:

  • 对58名新诊断的IDH野生型GBM或IDH突变Astro患者的分析,分为AFTV和对照组.
  • 对于PIK3R2和p53的免疫阻断,PIK3R2表达的评估使用了34%的截止值.
  • 评估患者的特征,包括年龄,性别,卡诺夫斯基性能状态和整体生存期 (OS).

主要成果:

  • 在AFTV组中,与对照组相比,PIK3R2阴性患者的生存率增加 (p=0.075对于GBM/Astro,p=0.030对于GBM).
  • 在p53-阴性/PIK3R2-阴性子组中,在GBM/Astro和GBM病例中都观察到显著的OS改善.
  • 在回归分析中,PD-1表达与PIK3R2的相关性最强.

结论:

  • 对PIK3R2和p53的负免疫染与接受AFTV治疗的GBM患者的存活率增加有关.
  • 这些生物标志物可以作为治疗疗效和整体存活率的预测指标,用于接受AFTV治疗GBM的患者.